Stanley Ginsburg
Neurology · Denver, CONPI 1225081581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $272 and has fallen 72.8% since, to $74 in 2025. That places this record below the midpoint for neurology clinicians in CO, where the typical reported total is $699.
Across 61 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$283
- Merz Pharmaceuticals, LLC$136
- Teva Pharmaceuticals USA, Inc.$99
- Lundbeck LLC$84
- UCB, Inc.$60
- EMD Serono, Inc.$51
- plus $507 from 21 others
What the payments were for
- Food & beverage$1,221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $283 |
| Merz Pharmaceuticals, LLC | 5 | $136 |
| Teva Pharmaceuticals USA, Inc. | 8 | $99 |
| Lundbeck LLC | 4 | $84 |
| UCB, Inc. | 2 | $60 |
| EMD Serono, Inc. | 2 | $51 |
| Eisai Inc. | 2 | $49 |
| Pfizer | 2 | $44 |
| Argenx US, Inc. | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $35 |
| MDD US Operations, LLC | 2 | $33 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Avion Pharmaceuticals | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Medtronic | 1 | $17 |
| Livanova USA, Inc. | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Biogen | 1 | $13 |
How this compares
$1,221 in reported general payments places this provider in the 50th percentile of 334 neurology providers in Colorado.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Michael AmentDenver$457K
- Adam WolffDenver$364K
- Shankar PerumalDenver$61K
- Jinny TaveeDenver$58K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.